Therapeutic Insights
Filter News
Found 1,008 articles
-
DIAN-TU-001 is a Phase II/III trial that tested two therapies compared to placebo, Genentech and Roche’s gantenerumab and Eli Lilly and Company’s solanezumab.
-
Cognoa Executives to Speak at DTx West 2020
2/10/2020
Palo Alto, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Cognoa , the leading digital therapeutics company focused on pediatric behavioral health, announced today that three company executives will be on stage at the third annual DTx West 2020 , taking place in San Mateo, California, February 18 to 20. All events take place on the first day of the conference, Tuesday, February 18. Details are as follows: At 10:15 a.m., Brent Vaughan, Co-founder and CEO of Cognoa will moderate a panel di
-
Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market
2/5/2020
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has entered into definitive agreements with several institutional and accredited investors
-
Investigators at the Case Western University School of Medicine identified a previously unknown gene and the resultant protein that may potentially slow the progress of Alzheimer’s disease.
-
Research conducted at Temple University is showing a potential new way to address the onset of Alzheimer’s disease through the use of pharmacological chaperones.
-
Novo Nordisk specializes in the diabetes market. The company appears to be making an entry into the Alzheimer’s market, which isn’t as unusual or unexpected as it initially sounds.
-
AstraZeneca’s Imfinzi (durvalumab) and tremelimumab were granted Orphan Drug designation by the U.S. Food and Drug Administration as a possible treatment for hepatocellular carcinoma.
-
Biogen is buying a novel CNS-penetrate inhibitor of casein kinase 1 (CK1) from Pfizer to develop for patients with behavioral and neurological symptoms in various psychiatric and neurologic diseases.
-
DBV announced positive topline results from its Phase III PEPITES trial evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children aged 4 to 11 years.
-
In the deal, Boehringer acquired worldwide exclusive rights to Enleofen’s preclinical interleukein-11 (IL-11) platform.
-
FARE said the biomarker research project, which will be conducted at Janssen’s World Without Disease Accelerator, “has the potential to make a real and significant impact for the 32 million Americans living with food allergies.”
-
Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January
12/26/2019
Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce that patient screening for its Phase 1 trial to investigate the use in healthy volunteers of delayed release tablets for colonic delivery of oral Brilacidin for treating Ulcerative Colitis,
-
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease
12/19/2019
As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline. -
In an effort to understand aging, researchers from Stanford University and colleagues around the world analyzed almost 3,000 proteins in the blood of more than 4,000 people ages 18 to 94.
-
The FDA approved extended-release 11 mg and 22 mg tablets as a once-daily treatment from the chronic inflammatory condition.
-
Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates
12/13/2019
Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Company approval to start its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.
-
Karuna’s work is primarily focused on psychosis related to schizophrenia and late-stage Alzheimer’s disease, as well as analgesic effects for pain.
-
Engitix and Morphic Enter Research Collaboration to Identify ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease (IBD)
12/10/2019
Engitix Ltd and Morphic Therapeutic announce that they have entered into a research collaboration to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease, an intestinal fibrosis complication that affects approximately 30 per cent of Crohn’s Disease patients.
-
Biogen presented full data today on its Alzheimer’s drug aducanumab at the 12th Clinical Trials on Alzheimer’s Disease conference held in San Diego.
-
The company presented full trial data at the 12th Clinical Trials on Alzheimer’s Disease meeting in San Diego on Wednesday.